ALS (Amyotrophic Lateral Sclerosis) Clinical Trial
— TCIM/ELAOfficial title:
Phase I Clinical Trial on Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis.
Verified date | March 2017 |
Source | Red de Terapia Celular |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety of Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis by a prospective, single-center, randomized, parallel, double-blind, placebo-controlled phase I clinical trial.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | December 2017 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of definite or probable ALS according to the criteria established by the World Federation of Neurology - Patient that provides reasonable assurance of adherence to protocol. - Neurophysiological data confirming affectation of lower motor neurons in the lumbar region. - Assessment of motor deficits in dorsiflexion of both feet (4 or 5 points on the MRC scale) - The patient must fulfill all inclusion criteria. Exclusion Criteria: - Diabetes Mellitus. - Other diseases that may present with polyneuropathy. - Previous history of stroke. - Prior Pathology of the peripheral nervous system affecting one or both lower limbs with or without clinically evident neurological sequelae. - Pregnant or breastfeeding patients active. - Patients physiologically capable of becoming pregnant, unless they are using reliable contraception. - Patients with cardiac disease, renal, hepatic, systemic, immune that may influence patient survival during the test. - Positive serology for hepatitis B, hepatitis C or HIV. - Clinical and anesthesiologic Criteria, contraindicating either sedation or extraction of MO (Altered coagulation system or anticoagulated patient with inability to withdraw anticoagulation, hemodynamic instability, altered skin puncture site, etc.) - Included in other clinical trials in the last 6 months. |
Country | Name | City | State |
---|---|---|---|
Spain | Clinical Universitary Hospital Virgen de la Arrixaca | El Palmar | Murcia |
Lead Sponsor | Collaborator |
---|---|
Red de Terapia Celular | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia, Hospital Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca, Public Health Service, Murcia, Spanish National Health System |
Spain,
Blanquer M, Moraleda JM, Iniesta F, Gómez-Espuch J, Meca-Lallana J, Villaverde R, Pérez-Espejo MÁ, Ruíz-López FJ, García Santos JM, Bleda P, Izura V, Sáez M, De Mingo P, Vivancos L, Carles R, Jiménez J, Hernández J, Guardiola J, Del Rio ST, Antúnez C, De — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of serious and non-serious adverse events related to the use of bone marrow mononuclear cells in patients with Amyotrophic Lateral Sclerosis. | 24 months from baseline | ||
Secondary | Estimated number of motor units (MUNE) | Several techniques for estimating the MUNE, all based on the relationship between the amplitude or area of compound muscle action potential (CMAP) and amplitude or area corresponding to a single motor unit response. The differences between the techniques are due to the different ways of estimating the amplitude of the responses for individual motor units. The study will use two techniques: Incremental Technique: The unitary amplitude (or area) of individual motor units are calculated from the responses to increasing intensities stimuli near of intensity threshold (Dantes and McComas, 1991) Statistical technique: The unit amplitude (or area) of the individual motor units are calculated from the amplitude variations (or area) of the muscle action potential obtained in response to stimuli from a fixed intensity (Daube, 2006) |
24 months from baseline | |
Secondary | Compound muscle action potential (CMAP) | CMAP is registered after supramaximal stimulation intensity (0.1-0.2 ms pulses at 1 Hz) of the common peroneal nerve at the level of the head of the fibula. The electrical stimulus is placed in a fixed position during the entire registration process. CMAP will be recorded simultaneously in 5 positions along longitudinally oriented TA muscle. To determine these 5 positions bony landmarks that are reproducible between members and between different patients will be used. | 24 months from baseline | |
Secondary | Fiber density (FD) | Quantifies the average number of muscle fibers per motor unit. It is obtained from single fiber recordings made with electrodes. The average number of motor unit potentials is calculated in 20 different positions in the muscle. | 24 months from baseline | |
Secondary | Muscle force MRC (Medical Research Council) score | 24 months from baseline | ||
Secondary | Maximum force developed in an isometric contraction of the tibialis anterior (TA) muscle. | The measurement will be done in Newtons, with a dynamometer during dorsiflexion of the foot (from certain angles). | 24 months from baseline | |
Secondary | Maximum transversal area of the tibialis anterior (TA) | The area will be measured in cm2 by echography. | 24 months from baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02528071 -
Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis
|
||
Active, not recruiting |
NCT03604822 -
Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS
|
N/A | |
Completed |
NCT02891629 -
Safety and Feasibility of the EyeControl Device
|
N/A | |
Completed |
NCT02164253 -
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
|
Phase 2 | |
Completed |
NCT00786032 -
A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients
|
N/A | |
Recruiting |
NCT03787420 -
Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS.
|
N/A | |
Recruiting |
NCT05663008 -
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
|
||
Recruiting |
NCT03330353 -
Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy
|
N/A | |
Active, not recruiting |
NCT03081338 -
A Programme for Amyotrophic Lateral Sclerosis Care in Europe
|
N/A | |
Active, not recruiting |
NCT03241784 -
T-Regulatory Cells in Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04849065 -
Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis
|
Phase 2 | |
Active, not recruiting |
NCT05276349 -
Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)
|
||
Completed |
NCT04090684 -
Ciprofloxacin/Celecoxib Combination in Patients With ALS
|
Phase 1 | |
Active, not recruiting |
NCT04055623 -
T-regulatory Cells in ALS
|
Phase 2 | |
Completed |
NCT02709330 -
ALS Reversals - Lunasin Regimen
|
Phase 2 | |
Completed |
NCT03482050 -
A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 1/Phase 2 |